1-3 of 3
Thomas Whitlow, BA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, PhD, Farrukh T. Awan, MD MS, Corrinne Hoffman, CNP, Kami J. Maddocks, MD, Mark Reid, CNP, Jennifer A. Woyach, MD, Thomas Whitlow, BA, Jeffrey A. Jones, MD MPH, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 693.
https://doi.org/10.1182/blood-2018-99-114169
Published: 2018
Journal Articles

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy Stark, MAS, Farrukh T. Awan, MD MS, Kami J. Maddocks, MD, Jennifer A. Woyach, MD, Thomas Whitlow, BA, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 431.
https://doi.org/10.1182/blood.V130.Suppl_1.431.431
Published: 2017
Journal Articles

Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A. Jones, MD MPH, Jennifer Woyach, MD, Farrukh T. Awan, Kami J. Maddocks, MD, Thomas Whitlow, BA, Amy S Ruppert, MAS, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 639.
https://doi.org/10.1182/blood.V128.22.639.639
Published: 2016